JNM (@journalofnucmed) 's Twitter Profile
JNM

@journalofnucmed

The journal of the Society of Nuclear Medicine and Molecular Imaging. Clinical investigations, basic science reports, continuing education articles and more.

ID: 1316406812942503938

linkhttps://jnm.snmjournals.org/ calendar_today14-10-2020 15:54:07

632 Tweet

3,3K Followers

163 Following

JNM (@journalofnucmed) 's Twitter Profile Photo

The growth of RPT requires a change in the training of radiopharmacists. ow.ly/BSa650SpH1G #NuclearMedicine #Theranostics #RPTherapy

JNM (@journalofnucmed) 's Twitter Profile Photo

Metastasis-directed therapy based on PSMA PET/CT is superior to choline-directed MDT. Learn more: ow.ly/f03y50SpH5C #NuclearMedicine #ProstateCancer #MolecularImaging Matteo Bauckneht

Metastasis-directed therapy based on PSMA PET/CT is superior to choline-directed MDT. Learn more: ow.ly/f03y50SpH5C 

#NuclearMedicine #ProstateCancer #MolecularImaging <a href="/MatteoBauckneht/">Matteo Bauckneht</a>
JNM (@journalofnucmed) 's Twitter Profile Photo

Is it safe? Is it effective? The answer in a study of more than 200 patients. ow.ly/JJLH50SwVrW #NuclearMedicine #ProstateCancer #RPTherapy

Is it safe? Is it effective? The answer in a study of more than 200 patients. ow.ly/JJLH50SwVrW

#NuclearMedicine #ProstateCancer #RPTherapy
JNM (@journalofnucmed) 's Twitter Profile Photo

Do different PSMA-targeted radiopharmaceutical therapies have different dosimetry profiles? ow.ly/iNGJ50SwVuu #NuclearMedicine #ProstateCancer #RPTherapy Jeremie Calais

Do different PSMA-targeted radiopharmaceutical therapies have different dosimetry profiles? ow.ly/iNGJ50SwVuu

#NuclearMedicine #ProstateCancer #RPTherapy <a href="/CalaisJeremie/">Jeremie Calais</a>
JNM (@journalofnucmed) 's Twitter Profile Photo

CMS proposes paying separately for any diagnostic radiopharmaceutical with a per day cost greater than $630 and removing their costs from the payment amounts for the #NuclearMedicine tests. Read more: ow.ly/GE7V50Sz5og. bit.ly/3S1dcFK.

JNM (@journalofnucmed) 's Twitter Profile Photo

State of the Art: The rise of molecular image–guided robotic surgery. ow.ly/hHtv50SBLRg #MolecularImaging #NuclearMedicine #RoboticSurgery

State of the Art: The rise of molecular image–guided robotic surgery. ow.ly/hHtv50SBLRg 

#MolecularImaging #NuclearMedicine #RoboticSurgery
JNM (@journalofnucmed) 's Twitter Profile Photo

Is Bombesin PET/CT imaging helpful in PSMA negative prostate cancer? ow.ly/QHlO50SWG5k #NuclearMedicine #ProstateCancer #MolecularImaging @DrLouiseEmmett

Is Bombesin PET/CT imaging helpful in PSMA negative prostate cancer? ow.ly/QHlO50SWG5k

#NuclearMedicine #ProstateCancer #MolecularImaging @DrLouiseEmmett
JNM (@journalofnucmed) 's Twitter Profile Photo

Forty-nine percent of #prostatecancer patients experienced changes in management based on posttreatment SPECT/CT. ow.ly/7O8N50SWGet #RPTherapy #NuclearMedicine Thomas Hope

Forty-nine percent of #prostatecancer patients experienced changes in management based on posttreatment SPECT/CT. ow.ly/7O8N50SWGet

#RPTherapy #NuclearMedicine <a href="/thomashopemd/">Thomas Hope</a>
JNM (@journalofnucmed) 's Twitter Profile Photo

¹⁷⁷Lu-PSMA (R)evolution in cancer care: Is it really happening? ow.ly/XPoA50SWGhH #RPTherapy #Cancer #NuclearMedicine

JNM (@journalofnucmed) 's Twitter Profile Photo

When mNET patients are eligible for PRRT and everolimus, PRRT should be used first in frail populations or when an objective response is needed. ow.ly/CS3x50SWGju #NETcancer #NuclearMedicine #RPTherapy

When mNET patients are eligible for PRRT and everolimus, PRRT should be used first in frail populations or when an objective response is needed. ow.ly/CS3x50SWGju

#NETcancer #NuclearMedicine #RPTherapy
JNM (@journalofnucmed) 's Twitter Profile Photo

Nearly 1,100 publications and five years later: Is FAP-targeted #theranostics really happening? ow.ly/UFAs50T4RVM #NuclearMedicine

JNM (@journalofnucmed) 's Twitter Profile Photo

¹⁸F-FDG PET/CT is useful in mapping out sites of disease recurrence in #BreastCancer patients with elevated CA 15-3. ow.ly/YvI950Tfn1k #NuclearMedicine #PETscan

¹⁸F-FDG PET/CT is useful in mapping out sites of disease recurrence in #BreastCancer patients with elevated CA 15-3. ow.ly/YvI950Tfn1k

#NuclearMedicine #PETscan
JNM (@journalofnucmed) 's Twitter Profile Photo

Navigating the future of #ProstateCancer care: AI-driven imaging and #theranostics through the lens of RELAINCE. ow.ly/V46h50Tfna0 #NuclearMedicine Michael Hofman